Featured
San Diego had fewer startup deals in the first quarter of this year. Health care startups led deal making.
The workforce reduction at Mirati Therapeutics will take place over the next year and impacts more than 400 employees.
San Diego’s biotech companies have raised sizable fundraising rounds recently, coming off a slower year in 2023. Another group of seasoned life science leaders also launched a new biotech with $400M
Local biotech Capstan Therapeutics exceeded its fundraising goal by $50 million despite a tough venture capital environment.
Marking the largest biotech deal in over a year, the drugmaker has leased two full buildings at a brand new life science campus in northern San Diego’s Torrey Hills community
Contineum Therapeutics filed to go public, making it San Diego’s second life science IPO of 2024
Genesis San Diego has leased out half of its eight-story building that’s dedicated to life science offices and wet labs
The local biotech is working on targeted cancer therapies for hard-to-treat tumors
Dexcom’s Stelo device will roll out this summer and it won’t require a prescription or medical insurance.
The annual expo, normally at Petco Park, made its debut this year at Snapdragon Stadium where more than 100 businesses, schools and organizations showcased their work in science and engineering.
QuidelOrtho’s CEO was terminated Wednesday and he resigned from the board
The San Diego biotechnology company also laid off its chief operating officer as it continues to cut costs and streamline operations
Cue Health grew rapidly in San Diego during the pandemic. The company has conducted multiple rounds of layoffs since demand and funding for COVID-19 tests has declined.
Company announces that layoffs at Illumina’s San Diego headquarters take effect on March 12
Number of deals in 2023 was lowest in five years, according to Venture Monitor data
The layoff comes after NuVasive was purchased by Globus Medical for $3.1 billion
The deal gives Sanofi access to Inhibrx’s therapy for a genetic disorder that raises a patient’s risk for lung cancer and other disease
Gilead purchased 27 acres of undeveloped land in 2022. Now, the pharma company says it will move part of its Oceanside workforce to Northern California.
